Trials / Unknown
UnknownNCT01680588
Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease
A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Navidea Biopharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 2, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of \[18F\]NAV4694 PET imaging in detecting beta-amyloid plaque in the brain in subjects with probable AD compared with healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [18F]NAV4694 |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2012-09-07
- Last updated
- 2016-03-30
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01680588. Inclusion in this directory is not an endorsement.